Literature DB >> 17121562

Prolonged use of dexmedetomidine in an infant with respiratory failure following living donor liver transplantation.

Yuki Enomoto1, Toyoichiro Kudo, Takashi Saito, Tetsuo Hori, Michio Kaneko, Akira Matsui, Taro Mizutani.   

Abstract

We used dexmedetomidine for more than 2 months in a mechanically ventilated infant without serious adverse effects. An infant with liver cirrhosis of unknown cause underwent living donor liver transplantation at the age of 9 months. Long-term mechanical ventilation was required postoperatively, and midazolam with fentanyl had been used to sedate the patient. They required increase to 1.7 mg.kg(-1).h(-1) and 3.5 microg.kg(-1).h(-1), respectively, which were still inadequate. On postoperative day 29, dexmedetomidine was added. The rate of dexmedetomidine infusion was increased gradually to 1.4 microg.kg(-1).h(-1). It was discontinued temporarily to exclude drug-induced liver dysfunction. However, without dexmedetomidine, adequate sedation level was unattainable. Liver dysfunction was likely to be attributed to cytomegalovirus infection and after restarting dexmedetomidine, the respiratory condition improved. He was extubated 10 weeks after the operation. Dexmedetomidine was successfully tapered off over the following 2 weeks with no signs of withdrawal. Dexmedetomidine was a useful sedative for an infant who required mechanical ventilation for a prolonged period of time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121562     DOI: 10.1111/j.1460-9592.2006.02008.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  11 in total

1.  Dexmedetomidine: Are There Going to be Issues with Prolonged Administration?

Authors:  Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

2.  Dexmedetomidine use in pediatric intensive care and procedural sedation.

Authors:  Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

3.  Prolonged Dexmedetomidine Infusion and Drug Withdrawal In Critically Ill Children.

Authors:  Astrid S Haenecour; Winnie Seto; Charline M Urbain; Derek Stephens; Peter C Laussen; Corrine R Balit
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Nov-Dec

4.  Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report.

Authors:  Timo Iirola; Ruut Laitio; Erkki Kentala; Riku Aantaa; Juha-Pekka Kurvinen; Mika Scheinin; Klaus T Olkkola
Journal:  J Med Case Rep       Date:  2010-02-25

Review 5.  Clinical uses of dexmedetomidine in pediatric patients.

Authors:  Hanna Phan; Milap C Nahata
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Dexmedetomidine Use in Critically Ill Children With Acute Respiratory Failure.

Authors:  Mary Jo C Grant; James B Schneider; Lisa A Asaro; Brenda L Dodson; Brent A Hall; Shari L Simone; Allison S Cowl; Michele M Munkwitz; David Wypij; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

7.  Analgesic effect of dexmedetomidine in a patient with herpetic stomatitis after living-donor lung transplantation.

Authors:  Yoshifumi Ohashi; Noriyuki Ohta; Osamu Hirao; Akinori Uchiyama; Takashi Mashimo; Yuji Fujino
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

8.  Safety and Effectiveness of Dexmedetomidine in the Pediatric Intensive Care Unit (SAD-PICU).

Authors:  Laura Carney; Jennifer Kendrick; Roxane Carr
Journal:  Can J Hosp Pharm       Date:  2013-01

9.  Sedation in intensive care unit: Is Dexmedetomidine the best choice?

Authors:  Vijay G Anand
Journal:  Int J Crit Illn Inj Sci       Date:  2012-01

Review 10.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.